FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972403965> ?p ?o ?g. }

• W1972403965 endingPage "875" @default.
• W1972403965 startingPage "866" @default.
• W1972403965 abstract "OBJECTIVES: Alosetron is a potent, selective 5-HT3 receptor antagonist prescribed for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D) under a risk management plan (RMP). The RMP was implemented following cases of ischemic colitis (IC) and complications of constipation (CoC) associated with the use of alosetron. The objectives of this study were to characterize IC and CoC clinical features, outcomes, and incidence rates in the new restricted patient population to evaluate the effectiveness of the RMP in the prevention of serious outcomes. METHODS: Safety data from adverse event reporting from November 2002 through June 2008 were reviewed for probable and possible IC and CoC using the US Food and Drug Administration/sponsor-defined criteria and definitions. Evidence for IC included medical documentation, colonoscopy, and sigmoidoscopy±biopsy. Evidence for CoC included medical history and confirmation from health-care professionals. RESULTS: Within the inclusion dates, 29,072 patients received 203,939 alosetron prescriptions. Although the absolute numbers of IC and CoC cases have declined, the incidence rates for IC and CoC (0.95 and 0.36 cases per 1,000 patient-years, respectively) were similar to rates during the postmarketing cycle before alosetron withdrawal. In patients with severe IBS-D receiving alosetron (n=998) or placebo (n=411) in clinical trials since reintroduction, incidence rates for IC were 4 and 2 cases per 1,000 patients, respectively. Rates for CoC were 2 and 0 cases per 1,000 patients in the alosetron and placebo groups, respectively. No mesenteric ischemia, surgeries, transfusions, or deaths occurred in patients with IC and no cases of CoC were associated with toxic megacolon, perforation, surgeries, transfusions, or deaths. IC and CoC cases were typically of short duration and all improved on prompt withdrawal of alosetron. CONCLUSIONS: Serious outcomes associated with IC and CoC appear to be mitigated since introduction of alosetron under the RMP." @default.
• W1972403965 created "2016-06-24" @default.
• W1972403965 creator A5017981196 @default.
• W1972403965 creator A5048152931 @default.
• W1972403965 creator A5089966912 @default.
• W1972403965 date "2010-04-01" @default.
• W1972403965 modified "2023-09-30" @default.
• W1972403965 title "Ischemic Colitis and Complications of Constipation Associated With the Use of Alosetron Under a Risk Management Plan: Clinical Characteristics, Outcomes, and Incidences" @default.
• W1972403965 cites W1490240745 @default.
• W1972403965 cites W1534348323 @default.
• W1972403965 cites W1968880098 @default.
• W1972403965 cites W1979205653 @default.
• W1972403965 cites W1980399821 @default.
• W1972403965 cites W1984023350 @default.
• W1972403965 cites W1987655442 @default.
• W1972403965 cites W1988306998 @default.
• W1972403965 cites W1993764725 @default.
• W1972403965 cites W1996004649 @default.
• W1972403965 cites W1997799955 @default.
• W1972403965 cites W2002414046 @default.
• W1972403965 cites W2007655479 @default.
• W1972403965 cites W2008019573 @default.
• W1972403965 cites W2017842002 @default.
• W1972403965 cites W2018343808 @default.
• W1972403965 cites W2027453870 @default.
• W1972403965 cites W2031072115 @default.
• W1972403965 cites W2035889417 @default.
• W1972403965 cites W2037900770 @default.
• W1972403965 cites W2038016377 @default.
• W1972403965 cites W2042335480 @default.
• W1972403965 cites W2044067755 @default.
• W1972403965 cites W2049197933 @default.
• W1972403965 cites W2054181324 @default.
• W1972403965 cites W2062440551 @default.
• W1972403965 cites W2067430156 @default.
• W1972403965 cites W2077365630 @default.
• W1972403965 cites W2078229815 @default.
• W1972403965 cites W2087399526 @default.
• W1972403965 cites W2090377492 @default.
• W1972403965 cites W2109750196 @default.
• W1972403965 cites W2121087428 @default.
• W1972403965 cites W2121184314 @default.
• W1972403965 cites W2126547777 @default.
• W1972403965 cites W2127837438 @default.
• W1972403965 cites W2132219482 @default.
• W1972403965 cites W2138969187 @default.
• W1972403965 cites W2335255541 @default.
• W1972403965 cites W4243057641 @default.
• W1972403965 cites W4249179916 @default.
• W1972403965 doi "https://doi.org/10.1038/ajg.2010.25" @default.
• W1972403965 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20197759" @default.
• W1972403965 hasPublicationYear "2010" @default.
• W1972403965 type Work @default.
• W1972403965 sameAs 1972403965 @default.
• W1972403965 citedByCount "75" @default.
• W1972403965 countsByYear W19724039652012 @default.
• W1972403965 countsByYear W19724039652013 @default.
• W1972403965 countsByYear W19724039652014 @default.
• W1972403965 countsByYear W19724039652015 @default.
• W1972403965 countsByYear W19724039652016 @default.
• W1972403965 countsByYear W19724039652017 @default.
• W1972403965 countsByYear W19724039652018 @default.
• W1972403965 countsByYear W19724039652019 @default.
• W1972403965 countsByYear W19724039652020 @default.
• W1972403965 countsByYear W19724039652021 @default.
• W1972403965 countsByYear W19724039652022 @default.
• W1972403965 countsByYear W19724039652023 @default.
• W1972403965 crossrefType "journal-article" @default.
• W1972403965 hasAuthorship W1972403965A5017981196 @default.
• W1972403965 hasAuthorship W1972403965A5048152931 @default.
• W1972403965 hasAuthorship W1972403965A5089966912 @default.
• W1972403965 hasConcept C120665830 @default.
• W1972403965 hasConcept C121332964 @default.
• W1972403965 hasConcept C121608353 @default.
• W1972403965 hasConcept C126322002 @default.
• W1972403965 hasConcept C141071460 @default.
• W1972403965 hasConcept C142724271 @default.
• W1972403965 hasConcept C204787440 @default.
• W1972403965 hasConcept C27081682 @default.
• W1972403965 hasConcept C2775862500 @default.
• W1972403965 hasConcept C2777043163 @default.
• W1972403965 hasConcept C2778435480 @default.
• W1972403965 hasConcept C2779896975 @default.
• W1972403965 hasConcept C2781112942 @default.
• W1972403965 hasConcept C2908647359 @default.
• W1972403965 hasConcept C526805850 @default.
• W1972403965 hasConcept C61511704 @default.
• W1972403965 hasConcept C71924100 @default.
• W1972403965 hasConcept C99454951 @default.
• W1972403965 hasConceptScore W1972403965C120665830 @default.
• W1972403965 hasConceptScore W1972403965C121332964 @default.
• W1972403965 hasConceptScore W1972403965C121608353 @default.
• W1972403965 hasConceptScore W1972403965C126322002 @default.
• W1972403965 hasConceptScore W1972403965C141071460 @default.
• W1972403965 hasConceptScore W1972403965C142724271 @default.
• W1972403965 hasConceptScore W1972403965C204787440 @default.
• W1972403965 hasConceptScore W1972403965C27081682 @default.
• W1972403965 hasConceptScore W1972403965C2775862500 @default.

• next